NYSEAMERICAN:STXS

Stereotaxis (STXS) Stock Price, News & Analysis

Stereotaxis logo
$0.81 +0.01 (+1.16%)
As of 09:45 AM Eastern
This is a fair market value price provided by Massive. Learn more.

About Stereotaxis Stock (NYSEAMERICAN:STXS)

Advanced

Key Stats

Today's Range
$0.83
▼
$0.83
50-Day Range
$0.80
▼
$1.40
52-Week Range
$0.80
▼
$2.86
Volume
1,709 shs
Average Volume
625,833 shs
Market Capitalization
$81.36 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.83
Consensus Rating
Buy

Company Overview

Stereotaxis develops robotic technologies for minimally invasive procedures, with a focus on treating heart rhythm disorders. Its systems are designed to help physicians guide catheters through blood vessels and within the heart during procedures such as cardiac ablation.

The company’s products include the Genesis Robotic Magnetic Navigation System, which uses externally controlled magnetic fields to steer compatible catheters, and the Odyssey platform for managing and displaying information in interventional procedure rooms. Stereotaxis also offers related devices and software for use in electrophysiology labs.

Founded in 1990 and based in St. Louis, Missouri, Stereotaxis serves hospitals and medical centers in the United States and internationally. Its technologies are intended to support physicians performing complex catheter-based procedures.

AI Generated. May Contain Errors.

Stereotaxis Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
58th Percentile Overall Score

STXS MarketRank™: 
2.90402023429 of 5 stars

Stereotaxis scored higher than 58% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Stereotaxis has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on no strong buy ratings, 4 buy ratings, no hold ratings, and no sell ratings.

  • Upside Potential

    Stereotaxis has a consensus price target of $2.83, representing about 253.0% upside from its current price of $0.80.

  • Amount of Analyst Coverage

    Stereotaxis has only been the subject of 3 research reports in the past 90 days.

  • Read more about Stereotaxis' stock forecast and price target.
  • Earnings Growth

    Earnings for Stereotaxis are expected to grow in the coming year, from ($0.22) to ($0.17) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Stereotaxis is -3.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Stereotaxis is -3.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Stereotaxis has a P/B Ratio of 5.73. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    6.60% of the float of Stereotaxis has been sold short.
  • Short Interest Ratio / Days to Cover

    Stereotaxis has a short interest ratio ("days to cover") of 8.4.
  • Change versus previous month

    Short interest in Stereotaxis has recently decreased by 7.27%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Stereotaxis does not currently pay a dividend.

  • Dividend Growth

    Stereotaxis does not have a long track record of dividend growth.

  • News Sentiment

    Stereotaxis has a news sentiment score of -0.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.59 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 10 news articles for Stereotaxis this week, compared to 1 article on an average week.
  • Search Interest

    Only 2 people have searched for STXS on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.
  • MarketBeat Follows

    3 people have added Stereotaxis to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Stereotaxis insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    16.03% of the stock of Stereotaxis is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    45.35% of the stock of Stereotaxis is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Stereotaxis' insider trading history.
Receive STXS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Stereotaxis and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

STXS Stock News Headlines

Stereotaxis (NYSEAMERICAN:STXS) Stock Price Target Cut by TD Cowen
You missed yesterday's deadline…
In June 2025, a drilling crew near the Grand Canyon uncovered an energy source producing nearly eight times the output of Saudi Arabia's largest oil well, enough potential energy to power civilization for two million years. While the One Big Beautiful Bill Act stripped tax credits from solar, wind, and EVs on July 4th, this discovery was reclassified alongside oil and nuclear and secured eight years of credits. Google signed a 15-year contract, and Bill Gates committed 100 million dollars.tc pixel
Stereotaxis (STXS) Q3 2026 Earnings Call Transcript
Stereotaxis Q3 Loss Flat, Revenue Rises; Shares Fall After Hours
Stereotaxis (STXS) Set to Post Earnings on Tuesday
See More Headlines

STXS Stock Analysis - Frequently Asked Questions

Stereotaxis' stock was trading at $2.30 at the beginning of the year. Since then, STXS stock has decreased by 65.1% and is now trading at $0.8027.

Stereotaxis Inc. (NYSEAMERICAN:STXS) announced its earnings results on Tuesday, November, 10th. The company reported ($0.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by $0.02. The business had revenue of $8.93 million for the quarter, compared to the consensus estimate of $9.60 million. Stereotaxis had a negative net margin of 70.86% and a negative trailing twelve-month return on equity of 144.02%.
Read the conference call transcript
.

Top institutional investors of Stereotaxis include State Street Corp (0.91%), Integrity Alliance LLC. (0.70%), Goldman Sachs Group Inc. (0.33%) and Empowered Funds LLC (0.12%).
View institutional ownership trends
.

Shares of STXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Stereotaxis investors own include NVIDIA (NVDA), Broadcom (AVGO), Tesla (TSLA), Palantir Technologies (PLTR), Micron Technology (MU), PayPal (PYPL) and Recursion Pharmaceuticals (RXRX).

Company Calendar

Last Earnings
11/10/2026
Today
11/17/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NYSEAMERICAN
Industry
Healthcare Equipment & Supplies
Sub-Industry
Healthcare Equipment
Current Symbol
NYSEAMERICAN:STXS
CIK
1289340
Employees
131
Year Founded
N/A

Price Target and Rating

High Price Target
$3.50
Low Price Target
$2.00
Potential Upside/Downside
+253.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.28)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$21.64 million
Net Margins
-70.86%
Pretax Margin
-74.24%
Return on Equity
-144.02%
Return on Assets
-35.66%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.42
Quick Ratio
0.95

Sales & Book Value

Annual Sales
$32.38 million
Price / Sales
2.48
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.14 per share
Price / Book
5.73

Miscellaneous

Outstanding Shares
100,200,000
Free Float
84,140,000
Market Cap
$80.43 million
Optionable
Not Optionable
Beta
1.40
7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

This page (NYSEAMERICAN:STXS) was last updated on 11/17/2026 by MarketBeat.com Staff.
From Our Partners